Interpace Biosciences, Inc. (IDXG)
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
Keeps a healthy share of every dollar it sells.
- Revenue
- $36.1M
- Net income
- $24.4M
- Net margin
- 67.6%
Little or no net debt.
- Total debt
- $974K
- Cash
- $2.7M
- Net debt / EBITDA
- -0.35x
Comfortably covers what is due within a year.
- Current assets
- $11.0M
- Current liabilities
- $5.0M
- Current ratio
- 2.22
The business funds itself from operations.
- Operating cash flow
- $4.5M
- Free cash flow
- $4.1M
- FCF margin
- 11.4%
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 5.5M
- Share growth (1y)
- 526.3%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IDXG Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 9.13 M | 9.03 M | 9.22 M | 8.76 M | 9.23 M |
| Revenue Growth (YoY) | -1.09 % | — | — | — | — |
| Cost of Revenue | 3.48 M | 3.13 M | 3.18 M | 3.32 M | 3.96 M |
| Gross Profit | 5.65 M | 5.90 M | 6.04 M | 5.44 M | 5.28 M |
| SG&A Expense | 5.18 M | 4.63 M | 4.33 M | 4.14 M | 5.57 M |
| R&D Expense | 149.00 K | 153.00 K | 142.00 K | 150.00 K | 173.00 K |
| Operating Expenses | 5.33 M | 4.78 M | 4.47 M | 4.29 M | 5.74 M |
| Operating Income | 321.00 K | 1.12 M | 1.58 M | 1.15 M | -468.00 K |
| Pretax Income | 330.00 K | 1.13 M | 1.53 M | 1.00 M | -533.00 K |
| Tax Provision | 64.00 K | 302.00 K | -21.22 M | -11.00 K | 0.00 |
| Net Income | 158.00 K | 721.00 K | 22.66 M | 911.00 K | -640.00 K |
| EPS (Basic) | 0.05 | 0.15 | 25.60 | 1.05 | -0.70 |
| EPS (Diluted) | 0.05 | 0.15 | 4.10 | 0.15 | -0.70 |
| Shares Outstanding | 5.54 M | 4.56 M | 885.80 K | 885.00 K | 884.60 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.